The Heparin Calcium Market is estimated to be valued at US$ 1,370.9 Mn in 2023 and is expected to exhibit a CAGR of 2.7% over the forecast period 2022 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market Overview:
Heparin calcium is an anticoagulant (blood thinner) drug extracted from animal tissues. It acts as an anticoagulant by inhibiting blood coagulation through a combination of prolonging thrombin time, inhibiting thrombin, disabling its interaction with factors V, VIII and fibrinogen, and increasing the activity of antithrombin III. It is mainly used to prevent blood clots from forming in blood vessels, arteries and veins during procedures such as dialysis, blood transfusions and cardiac surgery.

Market Dynamics:
The heparin calcium market is driven by increasing demand for anticoagulants and growing prevalence of coagulation disorders such as deep vein thrombosis (DVT), pulmonary embolism and atrial fibrillation. According to Centers for Disease Control and Prevention (CDC), atrial fibrillation affects over 2.7 million Americans annually. The risk of developing atrial fibrillation increases with age and the condition is more prevalent in men than women. Moreover, growing geriatric population base that is prone to chronic diseases and coagulation disorders is also expected to boost market growth during the forecast period.

Read More - https://makuv.com/the-global-heparin-calcium-market-projected-to-exhibit-steady-growth-over-the-forecast-period-2022-to-2030/